2 active not recruiting, 1 completed, 1 not yet recruiting. 2 Phase 1, 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Not yet recruiting 1 |
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma: new trials by email Literature Review of Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma trials Research Report on Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients Biospecimen Collection, Computed Tomography, Cyclophosphamide - Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma | Phase 1 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 20 | 2026-12-08 | 2026-07-20 |
| Zanubrutinib in Combination With R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma Cyclophosphamide, Doxorubicin Hydrochloride, Prednisone - Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Phase 1 | Active not recruiting | Yazeed Sawalha | 38 | 2021-11-16 | 2026-07-02 |
| Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma Biospecimen Collection, Computed Tomography, Cyclophosphamide - Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 422 | 2021-05-20 | 2026-10-27 |
| Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma External Beam Radiation Therapy, Pembrolizumab - Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Aggressive Non-Hodgkin Lymphoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 17 | 2018-02-01 | 2026-01-13 |
Lymphoma, Large B-Cell, Diffuse (3) · Lymphoma, B-Cell, Marginal Zone (1) · Lymphoma, Non-Hodgkin (1) · Lymphoma, T-Cell (1)
Hemic and Lymphatic Diseases (4) · Immune System Diseases (4) · Immunoproliferative Disorders (4) · Lymphatic Diseases (4) · Lymphoma (4) · Lymphoproliferative Disorders (4) · Neoplasms (4) · Neoplasms by Histologic Type (4) · Lymphoma, B-Cell (3) · Lymphoma, Non-Hodgkin (3)
CT-P10 (3) · Cyclophosphamide (3) · Doxorubicin (3) · Prednisone (3) · Rituximab (3) · deltacortene (3) · prednylidene (3) · Magnetic Resonance Spectroscopy (2) · Specimen Handling (2) · Vincristine (2) · Azacitidine (1) · Hyaluronoglucosaminidase (1) · cc-486 (1) · pembrolizumab (1) · polatuzumab vedotin (1)
Jonsson Comprehensive Cancer Center (1) · M.D. Anderson Cancer Center (1) · National Cancer Institute (NCI) (1) · Yazeed Sawalha (1)
United States (4)
Chelsea C Pinnix (1) · Elizabeth A Brem (1) · Sven De Vos (1) · Yazeed Sawalha, MD (1)
U10CA180888 (1)